Percutaneous coronary intervention in stable angina (ORBITA)

Symptomatic relief is the primary goal of percutaneous coronary intervention (PCI) in stable angina and is commonly observed clinically. However, there is no evidence from blinded, placebo-controlled randomised trials to show its efficacy. ORBITA is a blinded, multicentre randomised trial of PCI versus a placebo procedure for angina relief that was done at five study sites in the UK. Dr Rasha Al-Lamee is an Clinical Academic Interventional Cardiology Consultant at Imperial College Healthcare NHS Trust in London, UK. Dr Al-Lamee’s research interests are complex coronary intervention, coronary physiology and invasive intravascular assessment. She designed, conducted and led the ORBITA trial and is lead author of the primary publication in The Lancet.

Publication

Image courtesy of interviewee

Leave a Reply

Your email address will not be published.

×
You have insight(s) remaining for this month. Register for free and view thousands of insights in our archive today. Subscribe for unlimited access.
Copyright © Faculti Media Limited 2022. All rights reserved.
error:

Add the Faculti Web App to your Mobile or Desktop homescreen

Install
×